PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair

(2011) Arun Gupta et al.   CELL CYCLE

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors

(2010) B. McEllin et al.   CANCER RESEARCH

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

(2010) M. Graeser et al.   CLINICAL CANCER RESEARCH

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

(2010) A. Mukhopadhyay et al.   CLINICAL CANCER RESEARCH

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology

(2010) Laura Poliseno et al.   NATURE

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation

(2009) Michela Garofalo et al.   CANCER CELL

Combined PTEN and p27kip1 Protein Expression Patterns Are Associated with Obesity and Prognosis in Endometrial Carcinomas

(2009) A. Dellas et al.   CLINICAL CANCER RESEARCH

Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers

(2009) R. Natrajan et al.   CLINICAL CANCER RESEARCH

PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas

(2009) D. S.P. Tan et al.   CLINICAL CANCER RESEARCH

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective

(2009) Shahneen K. Sandhu et al.   EUROPEAN JOURNAL OF CANCER

Systemic therapy for recurrent endometrial cancer: a review of North American trials

(2009) Thanh H Dellinger et al.   Expert Review of Anticancer Therapy

Cellular Redistribution of Rad51 in Response to DNA Damage

(2009) Otto S. Gildemeister et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Concomitant PI3K–AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis

(2009) Lluis Catasus et al.   MODERN PATHOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

(2009) H. B. Salvesen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN

(2008) H. Yang et al.   CANCER RESEARCH

Tenets of PTEN Tumor Suppression

(2008) Leonardo Salmena et al.   CELL

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

(2008) B. Evers et al.   CLINICAL CANCER RESEARCH

Targeted therapy for cancer using PARP inhibitors

(2008) Christopher J Lord et al.   CURRENT OPINION IN PHARMACOLOGY

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE